LAKE FOREST, Calif.,
March 31, 2015 /PRNewswire/ --
Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of
advanced cryogenic logistics solutions for the life sciences
industry, serving markets including immunotherapies, stem cells,
cell lines, clinical research organizations, vaccine manufacturers,
animal health, and reproductive medicine, today announced that it
has been engaged to provide its cryogenic logistics services to
Roslin Cells of Edinburgh, United
Kingdom in support of Roslin's induced pluripotent stem
cell (iPSC) reprogramming service.
Roslin Cells is a global leader in the development and
production of human pluripotent stem cell lines to the life science
community for the development of new reagents, drugs and cellular
therapeutics. It is also establishing the Central Facility
for the European Bank for induced stem Cells (EBiSC) as part of a
€35 million program funded by the Innovative Medicines Initiative.
This aims to be the primary resource in Europe for high quality iPSCs.
As an effective and reliable liquid nitrogen vapor phase (LNVP)
logistics solution is critical to any cell based research program,
Cryoport's cryogenic logistics services are well positioned to
support this burgeoning research area that the life sciences
industry believes is critical to addressing many diseases.
Mr. Aidan Courtney, CEO of Roslin
Cells, commented, "Our vision is to establish a robust and cost
effective capacity to receive high quality iPSC samples from
researchers across Europe and to
be able to distribute them globally. Cryoport's technology
and capabilities provide validated cryogenic cold chain logistics
solutions which will allow us to realize these goals."
Mr. Jerrell Shelton, Cryoport's
CEO, stated, "As we further expand our operations in the European
Union, Cryoport takes great pride in having the opportunity to
support Roslin Cells in its continuing development and manufacture
of pluripotent stem cells for the life sciences community. This
relationship builds on our success to support leading cell therapy
programs and demonstrates our position in regenerative medicine in
Europe. Cryoport believes that iPSC research will play a
significant role in developing therapeutic options for patients
into the future and we are delighted to support Roslin Cells in our
critical cryogenic logistics role."
About Cryoport, Inc.
Cryoport is the premier provider of cryogenic logistics
solutions to the life sciences industry through its purpose-built
proprietary packaging, information technology and specialized cold
chain logistics expertise. We provide leading edge logistics
solutions for biologic materials such as immunotherapies, stem
cells, CAR-T cells, and reproductive cells for clients worldwide
including points-of-care, CRO's, central laboratories,
pharmaceutical companies, contract manufacturers, and university
researchers. Our packaging is built around our proprietary Cryoport
Express® liquid nitrogen dry vapor shippers, which are validated to
maintain a constant -150°C temperature for a 10 day dynamic
shipment duration. Our information technology centers around our
Cryoportal™ Logistics Management Platform, which facilitates
management of the entire shipment process. Cryoport is the
preferred cryogenic logistics solutions partner to the world's
largest shipping companies controlling more than 85% of the world's
air shipments. For more information, visit www.cryoport.com.
To download Cryoport's investor relations app, which offers
access to SEC documents, press releases, videos, audiocasts and
more, please click to download from your iPhone and iPad
or Android mobile device.
Forward Looking Statements
Statements in this news release which are not purely
historical, including statements regarding Cryoport, Inc.'s
intentions, hopes, beliefs, expectations, representations,
projections, plans or predictions of the future are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. It is important to note that the company's
actual results could differ materially from those in any such
forward-looking statements. Factors that could cause actual results
to differ materially include, but are not limited to, risks and
uncertainties associated with the effect of changing economic
conditions, trends in the products markets, variations in the
company's cash flow, market acceptance risks, and technical
development risks. The company's business could be affected by a
number of other factors, including the risk factors listed from
time to time in the company's SEC reports including, but not
limited to, the annual report on Form 10-K for the year ended
March 31, 2013. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in this press release. Cryoport, Inc.
disclaims any obligation, and does not undertake to update or
revise any forward-looking statements in this press
release.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cryoport-has-been-engaged-by-roslin-cells-for-logistics-support-of-roslins-ipsc-service-300058117.html
SOURCE Cryoport, Inc.